Posted inNews and Updates
Cholesterol Drug Race Faces Setback Amid Efficacy Concerns
A major cholesterol drug trial has failed to meet key expectations, casting uncertainty over the future of the multi-billion dollar cardiovascular market.
Posted inNews and Updates
Novartis-Backed Avidity Drug Faces Third Trial Setback
A Novartis-partnered drug candidate faces its third clinical trial failure. Explore the implications for RNA-targeted therapies and biopharma innovation.
Posted inNews and Updates
Osteoarthritis Drug Pipeline: Over 100 Firms Join Race
The osteoarthritis drug pipeline is expanding rapidly. Over 100 pharmaceutical firms are now developing novel treatments to target joint degeneration.
Posted inNews and Updates
AI-Designed Drug Reverses Biological Age: New Study Results
New clinical results show an AI-designed drug successfully reverses biological age markers. Discover the potential of this breakthrough in geroscience.
Posted inNews and Updates
New Proteomic Aging Clocks Transform Clinical Trial Design
New research shows how proteomic aging clocks can accelerate Phase 2a clinical trials, providing a faster way to measure the efficacy of geroprotective drugs.
Posted inNews and Updates
African Nations Unify Strategy to Strengthen Drug Regulation
African health ministers have launched a new strategy to harmonize medical regulations, aiming to improve drug safety and boost local manufacturing capacity.
Posted inNews and Updates
CF Pharmtech Gains NMPA Approval for IPF Drug Trial
CF Pharmtech gains NMPA clinical trial approval for ICF001 to treat IPF and PPF, marking a significant advancement in respiratory fibrosis research.
Posted inNews and Updates
Pulnovo Medical Launches US Trial for Pulmonary Hypertension
Pulnovo Medical has begun US enrollment for its PULSE-LHD trial, testing a novel pulmonary artery denervation system for patients with left heart disease.
Posted inNews and Updates
Dronabinol for PTSD: Can Synthetic THC Stop Nightmares?
New clinical trials explore dronabinol as a treatment for PTSD-related nightmares, raising critical questions about safety for patients with dual diagnosis.
Posted inNews and Updates
AriBio Shares Promising AR1005 Data for Lewy Body Dementia
AriBio reports positive Phase 2 data for AR1005 in treating Dementia with Lewy Bodies, showing promise in cognitive stabilization and safety for patients.